[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100649253":3},{"organization":4,"armGroups":7,"interventions":18,"overallOfficials":41,"centralContacts":46,"locations":54,"responsibleParty":98,"collaborators":100,"id":103,"slug":104,"hasResults":105,"nctId":106,"briefTitle":107,"officialTitle":107,"acronym":108,"eligibilityCriteria":109,"healthyVolunteers":105,"sex":110,"minAge":111,"maxAge":23,"enrollmentInfo":112,"targetDuration":23,"studyType":115,"phases":116,"briefSummary":118,"conditions":119,"keywords":125,"overallStatus":57,"whyStopped":23,"lastUpdateSubmitDate":137,"lastUpdatePostDateStruct":138,"startDateStruct":141,"completionDateStruct":143,"leadSponsor":145,"locationsCount":146},{"fullName":5,"class":6},"Fondazione Don Carlo Gnocchi ETS","OTHER",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"All enrolled patients","EXPERIMENTAL","Hospitalized patients aged ≥45 years admitted to cardiac, pulmonary, or orthopedic intensive rehabilitation units, or intermediate care units, for non-neurological conditions. All participants undergo a baseline clinical and cognitive screening visit (T0). Participants whose screening results suggest cognitive impairment undergo an extended neuropsychological assessment; those in whom cognitive impairment is confirmed additionally undergo blood sampling for APOE genotyping and plasma biomarkers of neurodegeneration (GFAP, NfL, pTau-217), a non-contrast brain CT scan, and, in a subset, multimodal neurophysiological assessment (resting-state EEG, auditory P300, actigraphy, polysomnography). Participants with confirmed cognitive impairment at T0 are re-assessed at a 12-month follow-up visit (T1).",[13,14,15,16,17],"Other: Cognitive and clinical screening","Other: Extended neuropsychological assessment","Diagnostic Test: Blood biomarker sampling and APOE genotyping","Diagnostic Test: Non-contrast brain CT scan","Diagnostic Test: Multimodal neurophysiological assessment",[19,24,28,33,37],{"type":6,"name":20,"description":21,"armGroupLabels":22,"otherNames":23},"Cognitive and clinical screening","Structured collection of clinical\u002Fsociodemographic variables (Cumulative Illness Rating Scale -CIRS-, Halm's Clinical Instability Scale -SIC-) and administration of the Montreal Cognitive Assessment (MoCA), Hospital Anxiety and Depression Scale (HADS), Lifestyle for Brain Health index (LIBRA), Cognitive Reserve Index Questionnaire-Short Version (S-CRIq), Motor Reserve Index Questionnaire (MRIq), and Current Physical Activity Questionnaire (cPAq), performed at baseline (T0) in all participants.",[9],null,{"type":6,"name":25,"description":26,"armGroupLabels":27,"otherNames":23},"Extended neuropsychological assessment","Digit Span\u002FCorsi Span (forward\u002Fbackward), Rey Auditory Verbal Learning Test, Rey-Osterrieth Complex Figure, SAND naming subtest, Trail Making Test A\u002FB, Stroop Colour-Word Test, and phonemic\u002Fsemantic\u002Falternate verbal fluency, administered at T0 in participants with screening results suggestive of cognitive impairment, and repeated at the 12-month follow-up (T1) in those with confirmed impairment.",[9],{"type":29,"name":30,"description":31,"armGroupLabels":32,"otherNames":23},"DIAGNOSTIC_TEST","Blood biomarker sampling and APOE genotyping","Venous blood draw for APOE genotyping, including APOE ε4 allele dose (0, 1, or 2 copies) and allelic frequency distribution (ε2, ε3, ε4) (T0 only), and quantification of plasma GFAP, NfL, and pTau-217 (all expressed in pg\u002FmL; T0 and T1), performed in participants with cognitive impairment confirmed by the extended neuropsychological assessment.",[9],{"type":29,"name":34,"description":35,"armGroupLabels":36,"otherNames":23},"Non-contrast brain CT scan","Single non-contrast brain CT scan performed at T0 in participants with confirmed cognitive impairment.",[9],{"type":29,"name":38,"description":39,"armGroupLabels":40,"otherNames":23},"Multimodal neurophysiological assessment","Resting-state EEG, quantified as relative spectral power in the delta, theta, alpha, and beta bands (T0 and, in participants with confirmed cognitive impairment, repeated at T1); auditory oddball P300 event-related potentials, quantified as latency and amplitude; actigraphy-based sleep-wake monitoring, quantified as Sleep Efficiency; and overnight polysomnography, quantified as percentage of total sleep time in each sleep stage (N1, N2, N3, and REM); performed at T0 in a subset of participants with confirmed cognitive impairment.",[9],[42],{"name":43,"affiliation":44,"role":45},"Cristina Polito","IRCCS Fondazione Don Carlo Gnocchi ETS, Firenze","PRINCIPAL_INVESTIGATOR",[47,51],{"name":43,"role":48,"phone":49,"phoneExt":23,"email":50},"CONTACT","+390557393653","crpolito@dongnocchi.it",{"name":52,"role":48,"phone":49,"phoneExt":23,"email":53},"Clinical Trial Unit","ctu@DONGNOCCHI.IT",[55,72,87],{"facility":56,"status":57,"city":58,"state":59,"zip":60,"country":61,"countryCode":62,"cosmosGeoPoint":63,"geoPoint":68,"contacts":69},"IRCCS Fondazione Don Gnocchi ETS","RECRUITING","Florence","FI","50143","Italy","IT",{"type":64,"coordinates":65},"Point",[66,67],11.24626,43.77925,{"lat":67,"lon":66},[70,71],{"name":43,"role":48,"phone":49,"phoneExt":23,"email":50},{"name":43,"role":45,"phone":23,"phoneExt":23,"email":23},{"facility":73,"status":57,"city":74,"state":75,"zip":76,"country":61,"countryCode":62,"cosmosGeoPoint":77,"geoPoint":81,"contacts":82},"IRCCS Fondazione Don Carlo Gnocchi ETS, Santa Maria Nascente","Milan","Michigan","20148",{"type":64,"coordinates":78},[79,80],12.59836,42.78235,{"lat":80,"lon":79},[83,86],{"name":84,"role":48,"phone":49,"phoneExt":23,"email":85},"Pietro Davide Trimarchi","ptrimarchi@DONGNOCCHI.IT",{"name":84,"role":45,"phone":23,"phoneExt":23,"email":23},{"facility":88,"status":57,"city":74,"state":75,"zip":89,"country":61,"countryCode":62,"cosmosGeoPoint":90,"geoPoint":92,"contacts":93},"Fondazione Don Carlo Gnocchi ETS, Istituto Palazzolo","20149",{"type":64,"coordinates":91},[79,80],{"lat":80,"lon":79},[94,97],{"name":95,"role":48,"phone":49,"phoneExt":23,"email":96},"Alessia Gallucci","agallucci@dongnocchi.it",{"name":95,"role":45,"phone":23,"phoneExt":23,"email":23},{"type":99,"investigatorFullName":23,"investigatorTitle":23,"investigatorAffiliation":23,"oldNameTitle":23,"oldOrganization":23},"SPONSOR",[101],{"name":102,"class":6},"University of Florence","100649253","prevalence-of-mild-cognitive-impairment-and-dementia-in-patients-admitted-to-non-neurological-rehabilitation-wards-100649253",false,"NCT07731334","Prevalence of Mild Cognitive Impairment and Dementia in Patients Admitted to Non-neurological Rehabilitation Wards","COGinREHAB","Inclusion Criteria:\n\n* Age ≥45 years\n* Hospitalization for at least 7-10 days for a non-neurological condition, in cardiac, pulmonary, or orthopedic intensive rehabilitation units, or intermediate care units\n* Adequate fluency in the Italian language\n* Provision of written informed consent\n\nExclusion Criteria:\n\n* Illiteracy\n* Severe, uncorrected visual impairment and\u002For hearing loss\n* Severe verbal communication deficit\n* Inability to remain seated for the duration of the assessment\n* Inability to use the dominant upper limb\n* Altered state of consciousness or alertness (e.g., delirium)\n* Severe scalp skin lesions or dermatitis precluding electrode application for neurophysiological recordings\n* Previous or current history of severe psychiatric disorders (e.g., psychotic disorders, bipolar disorder, severe major depressive disorder with psychotic symptoms, current suicidal risk, or other psychiatric conditions judged by the investigator to interfere with study participation, procedural compliance, or interpretation of results)\n* Previous history or current presence of clinically relevant neurological pathologies other than cognitive impairment (e.g., epilepsy, stroke, neurodegenerative diseases such as Parkinson's disease or multiple sclerosis, moderate-to-severe traumatic brain injury, brain tumors, central nervous system infections, or other neurological conditions that may influence cognitive, behavioral, or neurological functioning, or otherwise compromise the study objectives)","ALL","45 Years",{"count":113,"type":114},384,"ESTIMATED","INTERVENTIONAL",[117],"NA","Cognitive impairment is common among older adults hospitalized for non-neurological conditions but often goes unrecognized, particularly in rehabilitation settings where clinical attention is mainly focused on physical recovery. The COGinREHAB study is a multicenter, prospective, longitudinal interventional study conducted at three rehabilitation centers of the Fondazione Don Carlo Gnocchi in Italy (Florence and Milan).\n\nThe study will enroll 384 patients aged 45 years or older who are hospitalized for at least 7-10 days in cardiac, pulmonary, or orthopedic intensive rehabilitation units, or in intermediate care units, for conditions unrelated to the nervous system.\n\nAt admission, all participants undergo a clinical and cognitive screening visit. Patients whose screening results suggest possible cognitive impairment then undergo a more extensive neuropsychological evaluation. In those with confirmed cognitive impairment, additional blood tests are performed to measure biomarkers of neurodegeneration (GFAP, neurofilament light chain, and phosphorylated tau-217), together with APOE genotyping and a non-contrast brain CT scan. In a subset of these patients, resting-state EEG, auditory event-related potentials, actigraphy, and overnight polysomnography are also performed. Patients with confirmed cognitive impairment are invited to a follow-up visit 12 months later to assess whether their cognitive profiles and biological markers have changed.\n\nThe main purpose of the study is to estimate how frequently cognitive impairment occurs among patients admitted to non-neurological rehabilitation units, including how often it was previously undiagnosed. The study will also describe the clinical, biological, and neurophysiological profile of these patients and examine how cognitive impairment evolves over one year.",[120,121,122,123,124],"MCI","Mild Cognitive Impairment (MCI)","Mild Cognitive Impairment","Cognitive Deficit","Cognitive Decline",[122,126,127,128,129,130,131,132,133,134,135,136],"Cognitive Screening","Multimodal Assessment","Cognitive Trajectories","Dementia","Non-Neurological Rehabilitation","Plasma Biomarkers","Neurodegeneration","Neurophysiological Measures","Longitudinal Study","APOE Genotype","MoCA","2026-08-05",{"date":139,"type":140},"2026-08-10","ACTUAL",{"date":142,"type":140},"2026-01-20",{"date":144,"type":114},"2028-12",{"name":5,"class":6},3]